M. Eileen Dolan PhD
Professor of Medicine, Section of Hematology/Oncology
Program Co-Leader, Clinical and Experimental Therapeutics
The University of Chicago Comprehensive Cancer Center Chair
Committee on Clinical Pharmacology and Pharmacogenomics Chair
Committee on Reappointment of Assistant Professors
[email protected]
Dr. M. Eileen Dolan is a translational scientist with expertise in both preclinical models and clinical research. She works closely with physicians to evaluate pharmacogenomic endpoints in clinical trials. Dr. Dolan is well known for her work in developing modulators of DNA repair to enhance chemotherapy. Over the last decade, she has concentrated her research in the area of cancer pharmacogenomics. She is a leader in developing cell-based methods to identify genetic variants contributing to chemotherapeutic response and toxicity. Her laboratory was the first to demonstrate that chemotherapeutic induced cytotoxicity is a heritable trait, and the first to utilize lymphoblastoid cell lines as a model to demonstrate inter-ethnic differences in sensitivity to chemotherapy that recapitulates what is observed clinically for these drugs. Her laboratory developed a “triangle approach” to identify genetic variants associated with chemotherapeutic induced cytotoxicity, a model that has been adopted by other researchers within pharmacogenomics. She is well-funded as the principal investigator of an RO1 grant dedicated to identifying genetic variants associated with chemotherapy, a project within the University of Chicago Breast Cancer SPORE, and a project within the Pharmacogenetics of Anticancer Agents Research Group